Nuclear receptor peroxisome proliferator-activated receptor-c (PPARc) is an essential transcription factor for adipocyte differentiation. In mesenchymal stem cells, PPARc has been assumed to play a negative role in osteoblastic differentiation, by working in an adipogenesis dependent manner, due to the reciprocal relationship between osteoblast and adipocyte differentiation. However, the direct role of PPARc in osteoblast function is not fully understood, due in part to inadequate model systems. Here, we describe an adenoviral-mediated PPARc knockout system in which suppression of PPARc in mesenchymal stem cells enhanced osteoblast differentiation and inhibited adipogenesis in vitro. Consistent with this in vitro observation, lipoatrophic A-ZIP/F1 mice, which do not form adipocytes, displayed a phenotype in which both cortical and trabecular bone was significantly increased compared with wildtype mice. We next developed an inducible osteoblasttargeted PPARc knockout (Osx Cre/flox-PPARc) mouse to determine the direct role of PPARc in bone formation. Data from both in vitro cultures of mesenchymal stem cells and in vivo mCT analysis of bones suggest that suppression of PPARc activity in osteoblasts significantly increased osteoblast differentiation and trabecular number. Endogenous PPARc in mesenchymal stem cells and osteoblasts strongly inhibited Akt/mammalian target of rapamycin (mTOR)/p70S6k activity and led to decreased osteoblastic differentiation. Therefore, we conclude that PPARc modulates osteoblast differentiation and bone formation through both direct and indirect mechanisms. The direct mode, as shown here, involves PPARc regulation of the mTOR pathway, while the indirect pathway is dependent on the regulation of adipogenesis.
INTRODUCTION
Nuclear receptor peroxisome proliferator-activated receptor-c (PPARc) is an essential transcription factor for adipocyte differentiation. Evidence for this requirement is derived from observations that embryonic stem cells (ESC) from mice lacking PPARc are unable to differentiate into fat tissue [1] and that over-expression of PPARc in fibroblasts initiates adipogenesis [2] . Expression of PPARc is activated by naturally occurring fatty acids, peroxisome proliferators, and the thiazolidinedione (TZD) class of antidiabetic agents [3] . The TZDs, which function to lower blood glucose, have been widely used for the treatment of type 2 diabetes mellitus. Unfortunately, a significant side effect of this therapy is the potential for bone loss and subsequent skeletal fractures in diabetic patients [4] . This clinical consequence may be due to an imbalance between osteogenesis and adipogenesis when PPARc is overactivated in response to TZD [4] . However, the specific role of PPARc in osteogenesis is not fully understood.
A direct role for PPARc in bone formation has been difficult to determine because of the reciprocal regulation relationship that is hypothesized to exist between osteoblast and adipocyte differentiation of mesenchymal progenitor cells. For example, age-related osteoporosis is most often accompanied by an increase in bone marrow adipose tissue and it is believed that fat increases when osteoblasts are decreasd because progenitors form adipocytes instead of osteoblasts [5] . In contrast, PPARc-deficient ES cells fail to differentiate into adipocytes, but instead spontaneously differentiate into osteoblasts [1] . In transgenic animal models, PPARcAuthor contributions: H.S.: conception and design, collection and/or assembly of data, data analysis and interpretation, manuscript writing, and final approval of manuscript; J.K.K.: collection and/or assembly of data, data analysis and interpretation, manuscript writing, and final approval of manuscript; R.M.M. and P.L.M.: provision of study material, collection and/or assembly of data, data analysis and interpretation, and final approval of manuscript; K.D.H.: conception and design, financial support, data analysis and interpretation, and final approval of manuscript; P.H.K.: conception and design, financial support, data analysis and interpretation, manuscript writing and final approval of manuscript. insufficient mice exhibit high bone mass with increased osteogenesis and decreased adipogenesis [6] . Adipocytes also directly modulate osteoblast function through paracrine effects of secretory adipocytokines, such as adiponectin and leptin [7] [8] [9] [10] . Taken together, these data suggest that PPARc regulates bone formation in an indirect manner, a reciprocal effect of its primary modulation of adipogenesis and/or through adipocytokines. However, functional PPARc is also expressed in mouse and human osteoblasts [11] [12] [13] , which suggests that PPARc may play a direct role in regulating osteogenesis. One recent study indicates that osteoblast-targeted over-expression of PPARc significantly reduces bone mass in mice [14] . However, it has also been reported that over-expression of PPARc induces trans-differentiation of osteoblasts to adipocytes [15] . The PPARc over-expression mouse model is therefore not sufficient to completely understand the physiologic role of PPARc in osteogenesis. Moreover, recent evidence indicates that suppression of adipogenesis by inhibition of PPARc is not able to increase osteogenesis either in vitro or in vivo [16, 17] . Therefore, it is essential to determine the extent to which PPARc has a direct role in osteoblast function and bone formation.
Because the molecular mechanisms by which PPARc could regulate osteoblasts are not fully understood, we sought to determine how PPARc might interact with a key metabolic signaling pathway in bone. Mammalian target of rapamycin (mTOR) is the catalytic subunit of two distinct signaling complexes, mTOR complexes 1 and 2 (mTORC1 and mTORC2) [18] . mTORC1 activates ribosomal S6 kinase (S6K) and inactivates eukaryotic initiation factor 4E binding protein 1 (4EBP1) and thus stimulates protein synthesis, cell growth, cell proliferation, and progression through the cell cycle. Promotion of cell survival and cytoskeletal reorganization is also enhanced when mTORC2 activates Akt and PKCa [19] [20] [21] . Recent work also supports an important role of mTOR in the regulation of cell differentiation [22] [23] [24] [25] .
It is well known that the global protein translation level in stem cells is lower than differentiated cells, whereas the activation of protein translation in these stem cells can initiate differentiation [22] [23] [24] [25] . We, and others, recently demonstrated that mTOR signaling plays an essential role in osteoblast differentiation in vitro [26] [27] [28] [29] [30] . It is notable that rapamycin, an inhibitor of mTOR, inhibits osteogenesis both in vitro and in vivo [31] . Moreover, mTOR also plays an important role in PPARc-mediated adipogenesis [32, 33] . These data suggest a potential for crosstalk between the mTOR and PPARc pathways, both of which are important for osteogenesis. In this study, we used in vitro models and developed a new osteoblast-specific PPARc knockout mouse to study the physiologic role of endogenous PPARc in bone formation and found that the mTOR pathway was directly involved in PPARc-mediated modulation of osteogenesis and conclude that PPARc modulates bone formation through both direct and indirect mechanisms.
MATERIALS AND METHODS

Cell Culture
Bone marrow mesenchymal stem cells (BMSCs) were harvested and cultured as described previously [34, 35] with modifications. Briefly, femora and tibiae were dissected free of surrounding soft tissues. The aspirates were flushed with a-Modified Eagle's Medium (a-MEM; Invitrogen, Carlsbad, CA), and filtered through a 40-mm cell strainer. The marrow content of 4-6 bones was plated into a T75 culture flask in BMSC growth medium comprised of a-MEM containing 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 mg/mL streptomycin sulfate (Gibco, Grand Island, NY). Nonadherent cells were removed and adherent BMSCs were cultured and expanded for further experiments. Primary cells prior to passage four were used in the experiments. It is generally believed that BMSCs are the common progenitors for osteoblasts and adipocytes. As a primary cell type, BMSCs may more likely reflect the nature of cells of the bone marrow, in addition to their potential for clinical use when compared with cells lines. However, BMSCs are a heterogeneous population. Therefore, the well-defined bone marrow stromal cell line, ST2 [36] , which has osteoblast/adipocyte bipotential, is an ideal cell type for mechanistic studies on the reciprocal relationship between osteoblast and adipocyte differentiation. Similarly, the preosteoblast cell line MC3T3-E1 is an appropriate cell type to study molecular mechanisms when the cells have been committed to osteoblasts. ST2 and MC3T3-E1 cells were cultured in High Glucose Dulbecco's Modified Eagle Medium (HG-DMEM) containing 10% FBS, 100U/mL penicillin, 100 mg/mL streptomycin sulfate (Gibco, Grand Island, NY), and a-MEM containing 10% FBS, 100U/mL penicillin, and 100 mg/mL streptomycin sulfate, respectively.
PPARc was activated by 5 mg/mL Troglitazone (Trog, Cayman Chemical, Ann Arbor, MI), and the vehicle, dimethyl sulfoxide (DMSO, Sigma, St. Louis, MO.)-treated group was included as the control. BMSCs from PPARc flox/flox mice were transfected with adenovirus as described previously [9] with minor modifications. The cells were plated at a density of 20,000 cells/ cm 2 in T75 flasks. After 4 hours, virus was added at a multiplicity of infection of 1,000 in 4 mL a-MEM with 0.5% FBS. The virus-containing medium was removed and complete fresh medium was added after 4-hour cell transduction. Adenovirusexpressing cre recombinase (Ad-Cre) was harvested on February 19, 2009 , and viral titer was 2.40E11 plaque forming unit (PFU) per milliliter. Adenovirus CMVpLpA.dlE3 #1 (Ad-Blank) was harvested on February 18, 2001 , and viral titer was 1.30E11 PFU per milliliter.
Gene Expression Analysis
Polymerase chain reaction (PCR) analysis to detect knockout of PPARc by Ad-Cre was performed as described previously [37] with modifications. Genomic DNA in the transfected BMSCs was harvested using the DNeasy Blood and Tissue Kit (Qiagen, Germantow, MD). The primers for genotyping included one forward primer 2F: CTC CAA TGT TCT CAA ACT TAC and two reverse primers 1R: GAT GAG TCA TGT AAG TTG ACC and H5: GTA TTC TAT GGC TTC CAG TGC. Primer pair 2F/1R was designed to amplify the intact PPARc gene and the amplified length was 285 bp. Primer pair 2F/H5 was used to detect the deleted gene and the amplified length was 450 bp. Thermal cycling conditions were as follows: 95 C, 5 minutes, 40 cycles at (95 C, 30 seconds, 55 C, 30 seconds, 72 C, 45 seconds), 72 C, 5 minutes and 4 C. A 2% agarose-TAE gel electrophoresis followed by ethidium bromide staining was used to detect bands.
For the osteogenic and adipogenic gene expressions of the Ad-Cre BMSCs, the total RNA was isolated using the RNeasyMicro Kit (Qiagen, Germantow, MD). RNA concentration was determined at 260 nm and an equivalent amount of RNA sample (2 mg) was processed to generate cDNA using the High Capacity cDNA Reverse Transcript kit (Applied Biosystems, Forster City, CA). Quantitative PCR was performed by the SYBR Green PCR method using the ABI PRISM 7,500 sequence detection system (Applied Biosystems, Carlsbad, CA, USA). The housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used for normalization, GAPDH_F: TGA AGC AGG CAT CTG AGG G; GAPDH_R: CGA AGG TGG AAG AGT GGG AG. Primers for osteocalcin (OCN) and fatty acid binding protein 4 (FABP4) were: OCN_F: CAA GCA GGG TTA AGC TCA CA; OCN_R: GGT AGT GAA CAG ACT CCG GC [9] ; FABP4_-F:AAT GTG TGA TGC CTT TGT GG; FABP4_R: CAC TTT CCT TGT GGC AAA GC. Gene expressions in ST2 and MC3T3-E1 cells were performed with Taqman gene expression assays (Applied Biosystems, Forster City, CA). The genes analyzed were: GAPDH (Mm99999915), Runx2 (Mm00501584), OCN (Mm-03413826), and PPARc (Mm01184322) (Applied Biosystems, Forster City, CA).
In Vitro Mineralization Assays
The mineralization assay used for primary BMSCs was described previously [9] . Briefly, cells were plated in 12-well or 24-well plates at 20,000 cells/cm 2 . Plated cells were allowed to grow to confluence in growth medium. After reaching confluence, cells were cultured in osteogenic medium (BMSC Growth Medium-1 100 nM dexamethasone, 10 mM b-glycerophosphate, and 50 mM ascorbic acid 2-phosphate (all from Sigma, St. Louis, MO.)) for up to 14 days. The same protocol was used for ST2 and MC3T3-E1 cells except the osteogenic medium did not contain dexamethasone. Subsequently, cells were fixed with cold 70% ethanol for 1 hour, rinsed with water, stained for 10 minutes in 40 mM Alizarin red S (pH 4.2), and washed extensively with water. After imaging, the dye was eluted with 10% w/v hexadecylpyridinium chloride monohydrate (Wako, Chemical, Osaka, Japan) in 10 mM sodium phosphate pH 7.0 and concentration was determined by absorbance measurement at 562 nm. The results were normalized to total genomic DNA content.
In Vitro Adipogenic Differentiation Assays
The adipogenic differentiation assay was performed as described previously [9] . Briefly cells were plated at 40,000 cells per square centimeter and grown to confluence in HG-DMEM growth medium (HG-DMEM containing 10% FBS, 100U/mL penicillin, and 100 mg/mL streptomycin sulfate). Cells were induced with adipogenic medium (HG-DMEM growth medium 1 50 mM isobutylmethylxanthine (Sigma, St. Louis, MO.), 1 mM dexamethasone (Sigma, St. Louis, MO.), 167 nM insulin (Sigma, St. Louis, MO.), and 5 mg/mL Troglitazone (Cayman Chemical, Ann Arbor, MI)) for 2 days. Adipogenic maintenance medium (HG-DMEM Growth Medium 1 167 nM insulin) was then added for another 2 days. This process of induction medium followed by maintenance media was repeated three times. Cells were then fixed in zincbuffered formalin (Z-fix, Anatech LTD, Battle Creek, MI) for half hour and stained with oil red O solution (Sigma, St. Louis, MO.). Dye was eluted in 100% isopropanol and quantified at 500 nm. The results were normalized to total genomic DNA.
Genetically Modified Mice
Animal experiments were approved by the institutional animal care and use committee. PPARc-floxed mice [19] were crossed with tetracycline regulatable osterix-Cre mice [38] purchased from Jackson Laboratories (B6.Cg-Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/J; Stock Number: 006361). Mice were maintained on Doxycycline feed (Harlan Item #: TD.01306; Rodent Diet (2018, 625 Doxycycline) throughout the entire process of crossing the two lines to achieve homozygozity of the floxed PPARc allele. Mice that were Osx-Cre positive/PPARc f/f (experimental) or that were Osx-Cre negative/PPARc f/f or (control) were removed from the Doxycycline feed at weaning (3 weeks) and harvested at 6 months of age. For the in vitro experiments, BMSCs from the experimental and control mice were isolated, cultured and differentiated using the same methods as aforementioned. To further investigate the role of adipogenesis in bone formation in an in vivo context, we tested our hypothesis in A-ZIP/F1 fatless mice that do not form adipocytes due to the expression of a dominantnegative form of C/EBP under the FABP4 promoter [39] . AZip-F1 mice were provided by Dr. Chuck Vinson and harvested as indicated for evaluation of bone geometric parameters using microCT.
mCT 3D Reconstruction and Bone Morphometry
Femurs were fixed for 2 days with Z-fix (Anatech LTD, Battle Creek, MI), then moved to 70% ethanol, and scanned at a voxel size of 18 mm using a mCT scanner (GE Healthcare Pre-Clinical Imaging, London, ON). Micro View software (GE Healthcare Pre-Clinical Imaging) was used to generate a three-dimensional reconstruction from the set of scans. Assessment of bone microstructure was carried out according to the guidelines developed by Bouxsein et al. [40] . The region selected for cortical bone parameters was defined to be the central portion between the proximal and distal ends of the femur. Trabecular bone parameters were measured by analyzing the metaphyseal region adjacent to growth plate. User-defined contours were drawn every five images and interpolated for all images in between. The thresholds for cortical and trabecular bone were set to 2,000 and 1,200, respectively.
Western Blot Analysis
Primary BMSCs transfected with Ad-Cre/Ad-Blank after 3 days were harvested for Western Blot analysis. ST2 and MC3T3-E1 cells were treated with 50 mM bisphenol A diglycidyl ether (BADGE, Sigma, St. Louis, MO.) for 24 hours and harvested as well for Western Blot analysis as described previously [26] . Briefly, whole cell lysates were separated on 10% SDS-polyacrylamide gel and transferred to PVDF membrane. The membranes were incubated with 5% milk for 1 hour and incubated with primary antibodies overnight at 4 C. Primary antibodies used were as follows: polyclonal anti-phospho-AKT (1:500; Cell Signaling, Danvers, MA), polyclonal anti-AKT (1:1,000; Cell Signaling), polyclonal anti-phospho-p70S6K (1:500; Cell Signaling), polyclonal anti-p70S6K (1:1,000; Cell Signaling), polyclonal antiPPARc (1:1,000; Santa Cruz Biotechnology, Santa Cruz, CA), polyclonal anti-RUNX2 (1:1,000; Santa Cruz), and polyclonal antiOsteocalcin (1:1,000; Millipore). Blots were incubated with peroxidase-coupled secondary antibodies (Promega, Madison, WI) for 1 hour, and protein expression was detected with SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific, Rockford, IL). Membranes were reprobed with polyclonal anti-b-actin antibody (1:1,000; Cell Signaling) to control for equal loading.
Statistical Analysis and Image Editing
To determine statistical significance of observed differences between the study groups, a two-tailed homoscedastic t-test was applied. A value of p < .05 was considered to be statistically significant while 0.05<p < .10 was considered to represent a nonsignificant, but clear trend in cell or tissue response. Values are reported as the mean 6 SD. Brightness and contrast were adjusted equally across all images for improved visibility.
RESULTS
Knockout of PPARc in BMSCs Increases Osteogenesis and Inhibits Adipogenesis
Primary BMSCs were isolated from PPARc flox/flox mice to study the effects of PPARc gene knockout on adipogenesis and osteogenesis. PCR-based genotyping assays demonstrated robust LoxP recombination indicating loss of PPARc at the gene level (450bp band) in BMSCs after Ad-Cre delivery, while no band was detected in the control group (Ad-Blank) (Fig. 1A) . It was noted that residual intact PPARc (285 bp band) remained in the deleted group. Consistent with the essential role of PPARc in adipogenesis, the adipogenic differentiation of BMSCs was largely inhibited by in vitro PPARc gene knockout. When PPARc expression was abrogated, oil red O staining and FABP4 gene expression was diminished (Fig. 1B) . In contrast, PPARc knockout led to significantly increased mineralization and OCN gene expression in BMSCs (Fig. 1C) . This in vitro adenoviral-mediated PPARc knockout system therefore demonstrated that 
Osteogenesis Is Modulated by PPARc-Mediated Adipogenesis In Vitro and In Vivo
After a 2-week culture period in osteogenic medium, ST2 cells were strongly positive for Alizarin red S staining ( Fig. 2A) . This finding is in contrast to the effects observed when PPARc was activated. Mineralization of ST2 cells was inhibited when PPARc was activated by troglitazone, a PPARc ligand that supports PPAR activation. Accordingly, troglitazone-treated ST2 cells switched to an adipogenic phenotype with oil red Opositive lipid droplets accumulating in cultured cells ( Fig.  2A) , suggestings that osteogenesis was negatively modulated by PPARc-induced adipogenesis.
Micro-CT data from A-ZIP/F1 mouse long bones demonstrated a clear trend (0.05<p < .10) in which cortical bone was increased in A-ZIP/F1 relative to wild-type mice. These parameters included mean cortical thickness, bone mineral content (BMC) and bone mineral density (BMD). In line with this trend, the marrow area in A-ZIP/F1 bones was significantly lower than in wild-type mice (Fig. 2B) . Compared with cortical bone, the effects of adipogenic deficiency were more profound for trabecular bone formation in A-ZIP/F1 mice. The bone mCT values, including bone surface/bone volume (BS/BV) and trabecular spacing (Tb.Sp.), were significantly decreased, while trabecular number (Tb.N) was significantly increased in A-ZIP/F1 mice. The bone/tissue volume (BV/TV) ratio also indicated a higher trend (0.05<p < .10) in A-ZIP/F1 mice (Fig. 2C) . Therefore, both our in vitro and in vivo data indicated that PPARcmediated adipogenesis negatively regulated bone formation.
Osteoblast-Targeted PPARc Suppression Increased Osteogenesis In Vitro
Based on the opposing effects on mineralization when PPARc was either knocked out or activated, we hypothesized that the inhibitory effects of PPAR activation on bone formation were due, in part, to its proadipogeneic function. Therefore, to determine if PPARc had a direct role in osteogenesis that was independent on adipogenesis, BMSCs from osteoblast-targeted PPARc knockout mice were isolated and their capacity for osteogenic differentiation was examined. Compared with the BMSCs from WT mice, BMSCs from osteoblast-targeted PPARc knockout mice demonstrated much higher mineralization after 2 weeks in culture in osteogenic differentiation medium (Fig. 3A) . The finding that mineralization was enhanced when PPARc was blocked was corroborated in preosteoblastic MC3T3-E1 cells when they were treated with BADGE, an effective antagonist of PPARc (Fig. 3B) . The effects of PPARc inhibition on osteoblast-related gene expression in ST2 and MC3T3-E1 were tested after 24 hours BADGE treatment. Osteocalcin gene expression was enhanced by BADGE, while no significant difference was noticed for Runx2 expression in either cell type. Interestingly, expression of PPARc was also increased by BADGE treatment (Fig. 3C) . Taken together, these data suggest that PPARc in osteoblasts or preosteoblastic cells is able to modulate osteogenic differentiation through a direct manner in vitro. 
Osteoblast-Targeted PPARc Knockout Increases Trabecular Number in Adult Mice
To directly assess bone mass when PPARc is not expressed in osteoblasts, an inducible osteoblast-targeted PPARc knockout mouse model was developed. Femurs from control and experimental groups were harvested and analyzed at 6 months of age. Quantitative data from mCT analyses demonstrated that PPARc deletion in osteoblasts had little effect on cortical bone as they demonstrated similar mean thickness and marrow area (Fig. 4A, 4B ). In contrast, the structure of trabecular bone was significantly altered by deletion of PPARc in osteoblasts (Fig. 4A, 4C ). Among the trabecular analyses, trabecular number (Tb.N.) was significantly increased and trabecular spacing (Tb.Sp) was significantly decreased in PPARc KO mice. The bone volume fraction (BV/TV) also indicated a clear trend towards increasing BV/TV (0.05<p < .10) in KO mice (Fig. 4A, 4C) . Therefore, conditional deletion of PPARc in osteoblasts significantly increased trabecular number, while it had limited effects on cortical bone. These in vivo data also suggest that PPARc plays a direct role in osteoblastogenesis in addition to its primary role in adipogenesis.
Suppression of Endogenous PPARc Increases mTOR Signaling and Osteogenesis
The in vitro deletion of PPARc in BMSCs dramatically elevated phosphorylation of p70S6K (p-p70S6K), which is the primary down-stream effector of mTOR signaling (Fig. 5A) . Consistent with the increase in p-p70S6K, phosphorylation of AKT (p-AKT), which is one of the up-steam activators for mTOR signaling, was also enhanced when Ad-Cre was used to knockdown PPARc (Fig. 5A) . In complementary studies, the level of p-p70S6K was significantly increased in MC3T3-E1 and ST2 cells after 24-hour treatment with BADGE. It was noted that the basal level of p-p70S6K in ST2 cells was much lower than in 3T3-E1 cells. The levels of p-AKT were also increased in both cell types after BADGE-induced PPARc suppression. In addition, treatment with BADGE resulted in elevated levels of Runx2 and/or OCN in ST2 and MC3T3-E1 cells (Fig. 5B) . Consistent with the data supporting the hypothesis that PPARc influences osteoblast differentiation by inhibiting mTOR signaling, mineralization of MC3T3-E1 cells exposed to BADGE was severely inhibited by rapamycin treatment (Fig. 5C ), suggesting that rapamycin can rescue the loss of PPARc activity. These data indicate that endogenous PPARc in osteoblasts inhibited the activity of mTOR signaling, which is essential for osteogenesis. Consistent with the in vitro data, the levels of phosphorylation of p70S6K (p-p70S6K, red staining) in osteoblasts and osteocytes were clearly increased in the PPARc KO mice (Supporting Information Fig. 1) . Therefore, our data strongly suggest that the negative effects of PPARc on osteogenesis are partially mediated through inhibition of mTOR signaling.
DISCUSSION
In the current study, PPARc was specifically deleted in vitro and in osteoblasts in adult mice. Collectively, the data indicated that PPARc negatively regulates osteoblast differentiation and bone formation. Additionally, it was determined that PPARc inhibits mTOR signaling because either disruption of PPARc expression, or treatment with the PPARc inhibitor BADGE increases mTOR signaling and increases osteoblast differentiation.
In addition to adipogenesis, PPARc regulates a variety of physiologic processes including lipid metabolism, insulin sensitivity, inflammation, angiogenesis and osteoclastogenesis [3, [41] [42] [43] . Among these PPARc-mediated physiologic processes, adipogenesis, inflammation, angiogenesis and osteoclastogenesis are known to be involved in bone homeostasis [3, 41, [44] [45] [46] . However, due to overlapping signaling in these complex biologic functions, it is difficult to distinguish the direct role and mechanism of action for PPARc in osteogenesis [6, 47, 48] . Most of the available evidence suggests that the negative effects of PPARc on bone formation are through an adipogenesis-dependent mechanism. This conclusion may be explained by the reciprocal relationship between osteoblasts and adipocytes, which are both derived from mesenchymal stem cells [49] . Furthermore, TZD treatment is known to stimulate the secretion of adiponectin and tumor necrosis factor alpha (TNF-a) from fat tissue and thereby induce bone loss [50, 51] . However, the notion of a reciprocal relationship between adipogenesis and osteogenesis in the marrow is challenged by emerging data that suggest that the inhibition of adipogenesis is not always accompanied by increased osteogenesis [16, 17] . For example, systemic treatment with BADGE, a PPARc antagonist, effectively blocks type I diabetes-induced hyperlipidemia and bone marrow adiposity. However, BADGE treatment is not able to block type I diabetes-induced bone loss [16] . In line with this in vivo finding, BADGE and GW9662, two antagonists of PPARc, as well as lentivirus-mediated knockdown of PPARc, inhibit adipocyte differentiation from MSC without significantly affecting osteogenesis [17] .
Because of conflicting evidence linking adipogenesis and osteogenesis, we sought to directly study the contribution of PPARc in osteogenic differentiation. We isolated BMSCs from PPARc flox/flox mice and administered Ad-Cre to knockout PPARc in vitro. Before cell harvest and addition of Ad-Cre, the flox/flox mice have the same phenotype as wildtype mice. Use of this system eliminates the potential for systemic regulation of precursor cells that may otherwise be present in traditional phenotypically altered PPARc knockout animals. Moreover, compared with the chemical antagonists (BADGE and GW9662), the Ad-Cre assay has minimal side effects because it is designed to specifically target the PPARc gene. The in vitro data support the finding that PPARc is essential for adipogenesis and that osteogenic differentiation is enhanced when endogenous PPARc is deleted in BMSCs.
To further determine the effects of adipogenesis on bone formation, we used the A-ZIP/F1 mouse model. Adipogenesis in these mice is largely blocked due to the expression of a dominant-negative form of C/EBP under the adipocyte fattyacid-binding protein four (FABP4) promoter, while the expression of PPARc is not affected [39] . The mCT data demonstrated that both cortical and trabecular bone were significantly increased in these adipoatrophic mice. In contrast, when adipogenesis was induced by PPARc activation, osteogenesis was blocked in ST2 cells. It has also been reported that inhibition of adipogenesis in whole animals has profound effects in addition to regulation of osteogenesis. For example, in lipoatrophic A-ZIP/F1 'fatless' mice, and in mice treated with BADGE, marrow engraftment after irradiation is accelerated relative to wild-type or untreated mice [52] . This finding suggests that suppression of adipogenesis may not only enhance osteogenesis but may increase hematopoiesis as well.
In addition to the indirect adipogenesis-mediated effects of PPARc on osteogenesis, several lines of study from in vitro systems also suggest that PPARc may have a direct effect on osteoblast differentiation. It has been reported by several groups that functional PPARc is expressed in osteoblasts [11] [12] [13] .
Moreover, the pro-adipogenic and anti-osteoblastic PPARc activities can be separately activated by different ligands [53] . Further studies indicate that PPARc pro-adipogenic activity involves binding to peroxisome proliferator-activated receptorresponse element (PPRE) in gene regulatory regions while its anti-osteoblastic activity is PPRE-independent [54] . To study the role of PPARc in osteoblast function, we specifically deleted PPARc in osteoblasts by using the Cre/loxP system. BMSCs from the PPARc KO (Osx Cre/flox-PPARc) mice demonstrated a higher mineralization capacity compared with the cells from WT mice. Consistent with the in vitro results, the mCT analyses revealed that several trabecular bone parameters were significantly increased in PPARc KO mice compared with the WT mice. Our findings are supported by a recent report that in vivo over-expression of PPARc specifically in osteoblasts under the control of a 2.3-kb procollagen type 1 promoter negatively regulates bone mass in male mice [14] . It is noted that the overexpression model may result in more unexpected changes to the mice compared with our conditional KO model. Indeed, they disclose that osteoclastogenesis is significantly inhibited in mice overexpressing PPARc [14] . However, it is known that PPARc is a pro-osteoclastogeneic regulator in vitro and in vivo [45] . Moreover, over-expression of PPARc in osteoblasts unexpectedly increases adipogenesis of BMSCs in vitro although no significant difference in vivo was reported [14] . These drawbacks from the over-expression strategy are mitigated in the tetracycline (tet)-inducible Cre/loxP system (Tet-Off) used in our experiments. Tetracycline has been widely used in bone histomorphometry to label new bone formation [55] and to regulate the Cre recombinase gene in knockout mice [56] . Doxycycline, a member of the tetracycline family, was used in our control group to maintain normal PPARc functions by inhibiting the expression of Cre recombinase. However, it has been reported that tetracyclines are able to increase bone formation by both increasing osteoblast activity and inhibiting osteoclast function [57] . Therefore, the difference in bone formation due to PPARc knockout may be masked by doxycycline treatment, which is one of the possible reasons that BVF (p 5 0.07) did not achieve statistical significance in the KO group relative to the control group, because our control group was provided doxycycline to repress Cre activity.
Our data indicate that PPARc is able to regulate osteoblast differentiation and bone formation through both indirect and direct mechanisms. The indirect pathway is related to reciprocal differentiation as has been discussed previously. . PPARc modulates bone formation through direct and indirect mechanisms. The indirect pathway is dependent on adipogenesis, which includes not only the role of PPARc in the allocation of stem cells, but also the potential negative regulation derived from adipocytes. The direct mechanism is independent on adipogenesis. The endogenous PPARc in osteoblasts strongly inhibits the mTOR activity, thus inhibiting Runx2/Osteocalcin mediated osteoblastic differentiation. Abbreviations: MSC, mesenchymal stem cell; mTOR, mammalian target of rapamycin.
The direct regulation of osteogenesis, however, is not completely defined. Our recent work indicates that mTOR is directly involved in odontoblast and osteoblast differentiation [26, 27] . The contribution of mTOR to bone formation is further confirmed by a recent study in which significantly less bone formation and a lower trabecular bone mass was observed in rapamycin-treated C57BL/6 mice compared with the vehicle-treated controls [31] . It is intriguing that in the current study we demonstrated that the Akt/mTOR/p70S6K pathway was activated after knockout of PPARc in BMSCs, or by a PPARc antagonist in osteoblasts. Accordingly, osteoblastic markers were increased by the suppression of PPARc activity. Moreover, osteoblastic differentiation following the suppression of PPARc was blocked by rapamycin. Our data are consistent with the previous finding that rapamycin inhibits osteoblast differentiation, while over-expression of p70S6K significantly increases levels of Runx2 protein and Runx2 activity [29] . These results clearly indicate that the mTOR pathway is essential for osteoblast differentiation and that it is largely inhibited by endogenous PPARc in osteoblasts.
SUMMARY
In summary, our data demonstrate that PPARc modulates bone formation through bimodal mechanisms (Fig. 6) . The indirect pathway is dependent on adipogenesis, which includes not only the role of PPARc in the commitment of stem cells, but also the potential for negative regulation by adjacent mature adipocytes. The direct mechanism is independent of adipogenesis. The direct suppression of PPARc in osteoblasts significantly increases osteoblast differentiation and trabecular bone formation which is demonstrated in the Osx-PPARc knockout mouse model. We further demonstrate that endogenous PPARc in osteoblasts strongly inhibits mTOR activity, thus inhibiting osteoblastic differentiation.
